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Background/Aims. Genetic variants that aﬀect estrogen activity may inﬂuence the risk of Alzheimer’s disease (AD). In women with
Downsyndrome,weexaminedtherelationofpolymorphismsinhydroxysteroid-17beta-dehydrogenase(HSD17B1)toageatonset
and risk of AD. HSD17B1 encodes the enzyme 17β-hydroxysteroid dehydrogenase (HSD1), which catalyzes the conversion of
estrone to estradiol. Methods. Two hundred and thirty-eight women with DS, nondemented at baseline, 31–78 years of age, were
followedat14–18-monthintervalsfor4.5years.Womenweregenotypedfor5haplotype-taggingsingle-nucleotidepolymorphisms
(SNPs)intheHSD17B1generegion,andtheirassociationwithincidentADwasexamined.Results.Ageatonsetwasearlier,andrisk
ofADwaselevatedfromtwo-tothreefoldamongwomenhomozygousfortheminoralleleat3SNPsinintron4(rs676387),exon6
(rs605059), and exon 4 in COASY (rs598126). Carriers of the haplotype TCC, based on the risk alleles for these three SNPs, had an
almost twofold increased risk of developing AD (hazard ratio = 1.8, 95% CI, 1.1–3.1). Conclusion. These ﬁndings support experi-
mental and clinical studies of the neuroprotective role of estrogen.
1.Introduction
The neurotrophic and neuroprotective mechanisms of estro-
gen have beneﬁcial eﬀects on brain function that include
increasesincholinergicactivity[1–5],antioxidantactivity[6,
7], and protection against the neurotoxic eﬀects of beta amy-
loid [8–11]. Thus, the dramatic declines in estrogen fol-
lowing menopause may contribute to higher risk of AD in
women [12].
Allelicvariationingeneswithintheestrogenbiosynthesis
and estrogen receptor pathways may modify cerebral estro-
gen activity and inﬂuence risk of AD. The hydroxysteroid-
17beta-dehydrogenase(HSD17B1)gene,locatedonchromo-
some 17q11-q21, encodes the enzyme 17β-hydroxysteroid
dehydrogenase (HSD1), which catalyzes the conversion of
estrone to estradiol. Variants in HSD17B1 have been exam-
ined for their relation to hormone levels, [13, 14] breast can-
cer [13, 15–24], endometriosis and endometrial cancer [13,
25–29], colorectal cancer [30, 31], and prostate cancer
[32], with inconsistent results. Studies of polymorphisms
in HSD17B1 have focused on rs605059, a nonsynony-
mous single-nucleotide polymorphism in exon 6. The T/C2 Current Gerontology and Geriatrics Research
polymorphism in rs605059, the change in bases at codon
313 in exon 6, is expressed as the change in amino acids from
serine to glycine. The rs605059 SER313GLY variant has been
associated with a modestly increased risk of endometriosis,
estrogen receptor-negative tumors in breast cancer patients,
and colorectal cancer in women, conditions known to be
associated with estrogen regulation [16, 28, 29, 31], but not
all studies have found positive associations. Along with two
other haplotype-tagged SNPs, (rs676387 and rs598126),
these common variants represent over 80% of the variation
at this locus. [13]. Expression of HSD17B1 was found to
be increased in prefrontal cortex in late-stage AD [33], but
variants in HSD17B1 have not been examined for their
association with age at onset or risk of AD.
Women with Down syndrome (DS) are at high risk for
AD, with the onset of dementia 10–20 years earlier than
women in the general population [34–36]. Early age at
menopause and low levels of bioavailable estradiol in post-
menopausal women with DS are both associated with earlier
onset and increased cumulative incidence of AD [37, 38],
suggesting that the decline in estrogen contributes to patho-
logical processes leading to AD in this high-risk population.
In this study, we examined the relationships between single-
nucleotide polymorphisms in HSD17B1, age at onset, and
cumulative incidence of AD in women with DS to determine
if genotype was related to risk.
2.MaterialsandMethods
2.1.Subjects. Theinitialcohortincludedacommunity-based
sample of 279 women with DS. Of these 279 women, 252
(90.3%) agreed to provide a blood sample, and 244 (96.8%)
were genotyped for HSD17B1. All individuals were 30 years
of age or older at study onset and resided in New York,
New Jersey, Pennsylvania, or Connecticut. In all cases, a fam-
ily member or correspondent provided informed consent,
including blood sampling and genotyping, with participants
providing assent. The distribution of level of intellectual
disability and residential placement did not diﬀer between
participants and those who did not participate. Recruitment,
informed consent, and study procedures were approved by
the Institutional Review Boards of Columbia University
Medical Center and the New York State Institute for Basic
Research in Developmental Disabilities.
2.2. Clinical Assessment. Assessments were repeated at 14–
18-month intervals over ﬁve cycles of data collection and
included evaluations of cognition and functional abilities,
behavioral/psychiatric conditions, and health status. Cogni-
tive function was evaluated with a test battery designed for
use with individuals with DS varying widely in their levels of
intellectual functioning, as described previously [39]. Struc-
tured interviews were conducted with caregivers to collect
information on changes in cognition, function, and adaptive
behavior. Past and current medical records were reviewed for
all participants using a standardized protocol.
2.3. Classiﬁcation of Dementia. This is a longitudinal cohort
study of onset of AD in women with Down syndrome. The
classiﬁcation of dementia status, dementia subtype, and age
at onset was determined during consensus case conferences
where information from all available sources was reviewed.
Classiﬁcations were made blind to HSD17B1 genotype. We
classiﬁed participants into two groups, following the recom-
mendations of the AAMR-IASSID Working Group for the
Establishment of Criteria for the Diagnosis of Dementia in
Individuals with Developmental Disability [40]. Participants
were classiﬁed as nondemented if they were without cog-
nitive or functional decline, or if they showed some cogni-
tive and/or functional decline that was not of signiﬁcant
magnitude to meet dementia criteria (n = 164). Participants
were classiﬁed as demented if they showed substantial and
consistent decline over the course of follow up for at least
one-year duration and had no other medical or psychiatric
conditions that might mimic dementia (n = 80). Age at
meeting criteria for dementia was used to estimate age at
the onset of dementia. Of the 80 participants with dem-
entia, three had a history of stroke or TIA and were exclu-
ded from the analyses. Three additional participants were
also excluded because their ﬁndings suggestive of dementia
may have been caused by another non-AD medical or psy-
chiatric condition, leaving 164 nondemented and 74 dem-
ented women in the analysis. Only women with probable
or possible AD were included in the dementia group for
analysis.
2.4. DNA Isolation and Genotyping. Genomic DNA was ex-
tractedfromperipheralbloodleukocytesusingtheFlexiGene
DNA kit (Qiagen). Isolation of DNA and genotyping were
performed blind to the dementia status of the participant.
We analyzed 4 single-nucleotide polymorphisms (SNPs) in
HSD17B1 and one ﬂanking SNP (rs598126) in CoA synthase
(COASY), which is in high-linkage disequilibrium with
rs605059. These included rs605059 (SER313GLY, C > T),
which has been the SNP most consistently and strongly asso-
ciated with estrogen-related disorders. Additional tagging
SNPS were selected to provide coverage of the gene or to
include SNPs which had also been associated with estrogen-
related disorders in at least one study. These included rs2830
(T> C), rs2676530 (G > A), rs676387 (G > T), and rs598126
(C > T). Table 2 provides the locations and allele frequencies
of these SNPs. SNPs were genotyped using TaqMan PCR
assays (Applied Biosystems) with PCR cycling conditions re-
commended by the manufacturer, and by Prevention Genet-
ics using proprietary array tape technology. Accuracy of the
genotyping(≥97%)wasveriﬁedbyincludingduplicateDNA
samples by comparing the TaqMan and array tape data with
results of restriction digestion polymorphisms (RFLPs) for
several of the SNPs, and by testing for Hardy-Weinberg equi-
librium. Not all genotypes were available for all women at all
SNPs, so the numbers examined vary slightly by SNP.
2.5. Apolipoprotein E Genotypes. APOE genotyping was car-
riedoutbyPCR/RFLPanalysisusingHhaI(CfoI)digestionof
an APOE genomic PCR product spanning the polymorphic
(cys/arg) sites at codons 112 and 158, followed by acrylamide
gel electrophoresis to document the restriction fragmentCurrent Gerontology and Geriatrics Research 3
sizes [41]. Participants were classiﬁed according to the pres-
ence or absence of at least one APOE ε4a l l e l e .
2.6. Potential Confounders. Potential confounders included
levelofintellectualdisability,bodymassindex(BMI),ethnic-
ity,andthepresenceofanAPOEε4allele.Levelofintellectual
disability was classiﬁed as mild to moderate (IQ from 35 to
70) or severe to profound (IQ < 34), based on IQ scores ob-
tained before the onset of AD. BMI was calculated as weight
in kilograms divided by the squared height in square meters
(kg/m2) and was measured at each evaluation. The baseline
measure of BMI was used in the analysis and was included as
a continuous variable. Ethnicity was categorized as white or
nonwhite.
2.7. Statistical Analysis. Prior to association analysis, we
tested all SNPs for Hardy-Weinberg Equilibrium using the
HAPLOVIEW program [42], and all were found to be in
Hardy-Weinbergequilibrium.SNPswereanalyzedwithado-
minant model in which participants homozygous for the
common allele were used as the reference group, with the
exception of rs605059 and rs598126. We coded the C allele
at rs605059 as the high-risk allele since previous work
had shown that women carrying the C allele at rs605059
had lower levels of estradiol and a lower estradiol/estrone
ratio than women carrying the TT genotype [13]. We
coded the C allele as the high-risk allele in rs598126 since
previous work had shown the TT genotype to be associa-
ted with increased risk of breast cancer [15]. To code the
remaining genotypes, we used common alleles for HSD17B1
SNPs for Hapmap whites at the NCBI SNP web site
(http://www.ncbi.nlm.nih.gov/projects/SNP/). In prelimi-
nary analyses, the X2 test (or the Fisher’s exact test when any
cell had <5 subjects) was employed to assess the association
between AD and SNP genotypes as well as other possible
risk factors for AD including ethnicity, level of intellectual
disability, and the presence of an APOE ε4a l l e l e .A n a l y s i so f
variance (ANOVA) was used to examine BMI and age by AD
status.
The analysis was structured as a longitudinal cohort
study of the onset of AD. We used Cox proportional hazards
modeling to assess the relationship between HSD17B1 geno-
types, age at onset, cumulative incidence, and the hazard
ratio of AD, adjusting for ethnicity, BMI, level of intellectual
disability and the presence of an APOE ε4a l l e l e .T h et i m et o
event variable was age at onset for participants who deve-
loped AD and age at last assessment for participants who
remained nondemented throughout the follow-up period.
Because a set of three contiguous SNPs that span ∼10kb-
rs676387, rs605059, and rs598126 were signiﬁcantly asso-
ciatedwithAD,weperformedahaplotypeanalysistoidentify
haplotype(s) that may harbor a susceptibility variant(s) as
implemented in the PLINK program [43]. For nearly all
individuals, we were able to identify the most likely haplo-
types from the genotype data with a high degree of certainty
(i.e., the posterior probability approaching 1.0 for 91%
of the cohort with the rest exceeding probability >0.7).
Subsequently, we used the estimated haplotype as a “super-
locus”(analogoustoamicrosatellitemarker)toperformCox
Table 1: Demographic characteristics.
Characteristic Nondemented Alzheimer’s
disease
N 164 74
Age at baseline (M, SD)∗∗ 47.3 ± 6.9 54.2 ± 6.7
Level of intellectual disability (n,% )
Mild/moderate 97 (59.1) 35 (47.3)
Severe/profound 67 (40.9) 39 (52.7)
Ethnicity (n,% )
Non-hispanic white 142 (86.6) 68 (91.9)
Nonwhite 22 (13.4) 6 (8.1)
Body mass index (M, SD)∗∗ 29.9 ± 6.7 28.0 ± 6.0
Apolipoprotein E ε4a l l e l e( n, %) 34 (21.0) 20 (27.0)
∗∗P<0.05.
proportional hazards modeling. We restricted the analysis
to individuals with a posterior probability of carrying the
haplotype of 1.0.
3. Results
3.1. Demographic Characteristics. The mean age of partici-
pants at baseline was 49.4 years (range 31.5 to 78.1), and 88
percent of the cohort were white. The mean length of fol-
low-up was 4.5 (SD ± 2.4) years. Table 1 presents the demo-
graphic characteristics of the participants according to AD
status. Participants who developed AD over the follow-up
periodweresigniﬁcantlyolderatbaselinethannondemented
participants (54.2 versus 47.3 years) and were more likely
to have severe or profound level of intellectual function
(52.7% versus 40.9%), but did not diﬀer in the distribution
of ethnicity or the frequency of the APOE ε4a l l e l e .W o m e n
who developed AD had a signiﬁcantly lower BMI at baseline
thanwomenwhoremainednondementedoverthefollow-up
period. The mean age at onset of AD was 55.7 ± 6.4 years.
3.2. Analysis of SNPs in HSD17B1. Table 2 shows the loca-
tions and minor allele frequencies (MAFs) of HSD17B1
SNPs for Hapmap whites at the NCBI SNP web site (http://
www.ncbi.nlm.nih.gov/projects/SNP/)a n df o ro u rc o h o r to f
women with DS. Allele frequencies were similar in women
with DS to those observed in women without DS in the
general population. Table 3 presents the distributions of
HSD17B1 genotypes and the association between HSD17B1
SNPs and the hazard ratio of AD among women with Down
syndrome, adjusted for age, ethnicity, level of intellectual
disability, BMI, and the presence of an APOE ε4a l l e l e .A l lo f
the 5 SNPs examined were in high-linkage disequilibrium
(LD > 0.9, Figure 3). Three SNPs, rs676387, rs605059, and
rs598126, showed signiﬁcant associations with AD, the
strongest being with rs605059. Women who carried one or
two copies of the T allele at rs605059 were two to three times
more likely to develop AD than women homozygous for the
Ca l l e l e( H R= 2.0, 95% CI, 0.98–4.2 for those with the CT
genotype and HR = 3.0, 95% CI, 1.4–6.8 for those with the
TTgenotype)(Table3)andhadbothearlieronsetandhigher4 Current Gerontology and Geriatrics Research
Table 2: HSD17B1 SNP chromosomal locationa.
SNP Chromosome
positiona
Distance from
previous SNP
Minor
allele
MAFb
observed
MAF from
NCBI∗
SNP location
relative to
HSD17B1
rs2830 37958089 C 0.485 .392 Exon1
rs2676530 37959481 1392 A 0.230 .263 Intron 4
rs676387 37959799 318 T 0.259 .337 Intron 4
rs605059 37960432 633 T 0.482 .443 Exon 6
rs598126 37970046 9614 T 0.491 .429 Exon 4 of
COASY
aPhysical position on chromosome: Hg18, March 2006 assembly, dbSNP build 130.
bMAF: Minor allele frequency.
∗http://www.ncbi.nlm.nih.gov/.
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Figure 1:CumulativeincidenceofAlzheimer’sdiseasebyHSD17B1
rs605059 genotype in women with Down syndrome. TT - - - -.
CT....... CC—.
cumulative incidence of AD over followup (Figure 1). The
eﬀects of carrying risk alleles for rs605059 were primarily
s e e ni nw o m e no v e r6 0y e a r so fa g e( F i g u r e1).
The relation of rs676387 and rs598126 to increased risk
forADwasseenonlyamongwomenhomozygousfortherisk
allele (Table 3) and was associated to a two- and one half-
fold hazard ratio (HRrs676387 = 2.7, 95% CI: 1.2–5.8 and
HRrs5998126 = 2.2, 95% CI: 1.1–4.4) and with earlier onset
but not higher cumulative incidence of AD (Figures 2(a) and
2(b)).
3 . 3 .H a p l o t y p eA n a l y s i so ft h eT h r e eS N P si naC o xP r o p o r -
tional Hazards Modeling. We ﬁrst computed the most likely
haplotypes for each individual and then used the haplotypes
as a “super locus” to estimate hazard ratios controlling
for potential confounders. Our haplotype analysis using
rs676387-rs605059-rs598126 revealed that the carriers of
Table 3: Alzheimer’s disease risk by HSD17B1 genotype in women
with Down syndrome.
HSD17B1 genotype∗ N AD HR (95% CI)∗∗
rs2830
CC 49 15 (30.6) 0.7 (0.3.5)
CT 101 31 (33.7) 0.9 (0.5–1.8)
TT 56 15 (26.8) 1.0 (reference)
rs2676530
AA 14 7 (50.0) 1.5 (0.7–3.3)
AG 75 17 (22.7) 0.7 (0.4–1.2)
GG 135 47 (34.8) 1.0 (reference)
rs676387
TT 22 9 (40.9) 2.7 (1.2–5.8)
GT 72 23 (31.9) 1.4 (0.8–2.4)
GG 129 40 (31.0) 1.0 (reference)
rs605059
CC 59 20 (33.9) 3.0 (1.4–6.8)
CT 107 34 (31.8) 2.0 (0.98–4.2)
TT 51 12 (23.5) 1.0 (reference)
rs598126
CC 58 15 (34.) 2.2 (1.1–4.4)
CT 119 37 (31.1) 1.4 (0.7–2.6)
TT 54 20 (27.8) 1.0 (reference)
∗∗Hazard ratio for AD, adjusted for age, ethnicity, level of intellectual dis-
ability, BMI, and the presence of an APOE ε4a l l e l e .
∗Numbers vary because not all participants were genotyped for all SNPs.
haplotype TCC had earlier onset of AD, after adjusting for
the presence of an APOE ε4, allele level of intellectual dis-
ability, ethnicity, and BMI (hazard ratio = 1.8, 95% CI, 1.1–
3.1).
4. Discussion
ThreeoftheﬁveSNPsexaminedinHSD17B1wereassociated
with increased risk of AD. Women who were heterozygous
or homozygous for the C allele at rs605059 were two to
three times as likely to develop AD as those carrying the TTCurrent Gerontology and Geriatrics Research 5
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Figure 2: (a) Cumulative incidence of Alzheimer’s disease by HSD17B1 rs598126 genotype in women with Down syndrome. TT ---- .
CT.......CC—.(b)CumulativeincidenceofAlzheimer’sdiseasebyHSD17B1rs676387genotypeinwomenwithDownsyndrome.CC - - - -.
CT.......T T — .
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Figure 3: Linkage disequilibrium patterns for SNPs in HSD17B1.
genotype. Women with DS homozygous for the T allele at
rs676387 or the C allele at rs598126 had 2.7 and 2.2-fold
increased risk of AD, respectively, compared with women
without these risk alleles, although risk was only slightly in-
creased in women who were heterozygous for the risk allele.
Carrying a high-risk allele at rs605059 was associated with
both early onset and higher cumulative incidence, while
carrying a high-risk allele at rs676387 or at rs598126 was
associatedprimarilywithearlieronset.Haplotype-basedCox
proportional hazards model continued to support that TCC
carriers had an almost 2-fold risk of developing AD after
adjusting for covariates.
Polymorphisms or haplotypes in HSD17B1 have been
associated with increased risk for estrogen receptor-negative
breast cancer, endometriosis, and endometrial cancer, but
these associations have been modest and inconsistent [13,
15–32]. The HSD17B1 gene encodes the enzyme HSD1
which catalyzes the conversion of estrone to estradiol. One
pathway by which variants in HSD17B1 could inﬂuence risk
for AD is through changing the activity of HSD1 leading to
changes in circulating estrogen levels. After menopause, the
primary form of estrogen is estrone, which is formed in
adiposetissue,muscle,liver,bonemarrow,brain,andﬁbrob-
lastsfromaromatizationofcirculatingandrostenedione[44].
Increased body mass index in postmenopausal women is
correlated with higher levels of serum estradiol and estrone
[45, 46]. Low BMI has been found to be a risk factor for
cognitive decline and risk for AD in late life [39, 47–49], and
BMI may decline decades before onset of AD [50]. Among
postmenopausal women not using hormone replacement
therapy, nonobese women (<25BMI) who were heterozy-
gous or homozygous for the C allele at rs605059 had lower
levels of estradiol and a lower estradiol/estrone ratio than
women carrying the TT genotype [13], while no correspon-
dingeﬀectsonestr oneorestradiollev elsw er eseeninw omen
with BMI >25. Our results showing earlier age at onset and
higher cumulative incidence of AD among women carrying
the C allele at rs605059 are consistent with this ﬁnding.
Among non-obese women, variants in HSD17B1 have also
been associated with a more rapid rate of decline in estradiol6 Current Gerontology and Geriatrics Research
levels during the perimenopausal period [51]. Low estrogen
levels have been associated with increased risk of cognitive
impairmentandAD[38,52–59],althoughsomestudieshave
f o u n dh i g hl e v e l so ft o t a le s t r a d i o li nw o m e nw i t hA D[ 60,
61].AroleforlowestrogeninADhasalsobeensupportedby
experiments in which estrogen deﬁciency accelerated amy-
loid plaque formation in transgenic mouse models of AD
[62, 63]. The ﬁndings from this study are consistent with a
role for HSD17B1 in modifying risk of AD through inﬂu-
encesonperipheralorcentralestrogenlevelsandpointtothe
potentialforhormonalreplacementtherapytodelayonsetof
AD in this high-risk population.
HSD17B1 belongs to the family of short-chain dehydro-
genases/reductases (SDRs) of which at least 11 other 17-beta
HSDtypesareunderstudy,namedfortheirsequencehomol-
ogy to HSD17B1 [64]. One of these, 17-beta HSD10, has
demonstrated involvement with AD through binding with
amyloid-beta [65]. While the substrate activity of HSD17B1
is quite restricted, unlike that of 17beta HSD10, the multi-
functionality of all SDRs is just beginning to be explored. For
example, increased expression of HSD17B1 and aromatase
have been found in the prefrontal cortex of AD patients
during the later stages of the disease [33]. It has been sug-
gested that estradiol is upregulated in astroglia during AD,
much as it is in reactive astroglia following brain injury,
and increased expression of aromatase and HSD17B1 may
determine diﬀerences in levels of protective neurosteroids in
theprefrontalcortex[33].Continuedworkongeneticfactors
aﬀectingneurosteroidactivitymayhelptounderstanddiﬀer-
ences in rates of cognitive aging and risk of dementia.
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